Therapeutic targeting of N-cadherin expression or further upstream targets, possibly by transfection with siRNA or miRNA as detailed in vitro by the authors mentioned in Table 1, may help slow the progression of osteosarcoma or possibly serve as an adjunct to primary therapy to mitigate metastasis. The gene discussed is CDH2; the disease is osteosarcoma.